Last reviewed · How we verify
Tazarotene cream
At a glance
| Generic name | Tazarotene cream |
|---|---|
| Sponsor | Stiefel, a GSK Company |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Investigator Initiated Trial to Study Duobrii® Lotion in the Treatment of Mild Plaque Psoriasis in Adults (PHASE3)
- Anti-Inflammatory Effects of 0.045% Tazarotene/0.01% Halobetasol Lotion in Psoriasis (PHASE4)
- Comparing the Efficacy of Topical Tazarotene Gel 0.1% v/s Microneedling in Atrophic Post Acne Scars (PHASE2, PHASE3)
- Differin® Gel x12 Wks vs Tazorac® Cream x12 Wks vs Differin® x6 Wks Switched to Tazorac® x6 Wks for Treatment of Acne (PHASE4)
- Efficacy of Tazarotene in Treatment of Verruca Plana (PHASE2)
- Dose Range Study of CD5789 in Acne Vulgaris (PHASE2)
- A Bioavailability Study of DFD-03 Compared to Tazorac® in Patients With Moderate Acne Vulgaris (PHASE2)
- Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Face (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tazarotene cream CI brief — competitive landscape report
- Tazarotene cream updates RSS · CI watch RSS
- Stiefel, a GSK Company portfolio CI